OncoMatch/Clinical Trials/NCT06832865
ELISA in Relapsed/Refractory MM
Is NCT06832865 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including elranatamab and Isatuximab SC for relapsed refractory multiple myeloma (rrmm).
Treatment: elranatamab · Isatuximab SC · Isatuximab SC-OBDS — This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug
Must have received: proteasome inhibitor
Cannot have received: anti-bcma bispecific t cell engager
Lab requirements
Blood counts
ANC ≥ 1000/μL (no G-CSF within 7 days); Platelet count ≥ 50,000/µL (no platelet transfusion within 7 days); Hemoglobin ≥ 8 g/dL (RBC transfusions permitted)
Kidney function
Calculated creatinine clearance of ≥ 30 mL/min by Cockcroft-Gault equation
Liver function
Serum bilirubin values < 2 mg/dL (Gilbert's syndrome <3 mg/dL and normal direct bilirubin); ALT and/or AST < 2.5 × ULN
Cardiac function
Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
Participants must have adequate organ and marrow function as defined below: ... see criteria above.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify